[1] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva, 2007.
[2] WHO Human Papillomavirus (HPV). Available at http://www.who.int/immunization/topics/hpv/en/
[3] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva, 2007
[4] WHO position paper: Human papillomavirus vaccines. Geneva 2009.
[5] Palefsky JM, Holly EA Molecular virology and
epidemiology of human papillomavirus and cervical cancer. Cancer
Epidemiol Biomarkers Prevent 4:425-428, 1998.
[6] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007
[7] WHO Cervical cancer screening in developing countries. Geneva 2002.
[8] WHO position paper 2009, op cit.
[9] Parham G et al. Effectiveness of a programme to prevent cervical
cancer among HIV-infected women in Zambia. Seventeenth Conference on
Retroviruses and Opportunistic Infections, San Francisco, abstract 29, 2010.
[10] Clifford GM, Polesel J and Rickenbach
M Cancer risk in the Swiss HIV
Cohort Study: associations With immunodeficiency, smoking, and highly active antiretroviral therapy. Journal of the National Cancer Institute 97 (6), 2005.
[11] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007.
[12] Manhart LE, Koutsky
LA Do condoms prevent genital HPV infection,
external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29:725-735, 2002.
[13] Moscicki AB et al. Risks for incident human
papillomavirus infection and low-grade squamous intraepithelial lesion
development in young females. JAMA. 285:2995-3002, 2001.
[14] Ley C et al. Determinants of genital human papillomavirus infection
in young women. J Natl Cancer Inst.83:997-1003, 1991.
[15] Koutsky L Epidemiology of genital human papillomavirus infection.
Am J Med.102:3-8, 1997.
[16] Smith EM, Johnson SR, Ritchie JM et al. Persistent HPV infection in
post menopausal age women. Int. J Gynaecol Obstet. 87:131-137, 2004.
[17] WHO
Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points for
policy-makers and health professionals. Geneva 2007.
[18] Melnikow
J et al. Natural history of cervical
squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 1998;92:727-35
[19] Hogewoning CJA et al. Condom use promotoes regression of cervical
intraepithelial neoplasia and clearance of human papilloma virus: a randomised
clinical trial. Int J Cancer 107: 811-816, 2000.
[20] WHO position paper 2009, op cit..
[21] Bosch FX et al. Epidemiology and natural history of human papillomavirus
infections and type-specific implications in cervical neoplasia. Vaccine26
(Supplement 10): K1–16, August 2008.
[22] Schwartz SM, Daling JR et al. Human papillomavirus and
prognosis of invasive cervical cancer: A population-based study. JCO vol. 19 no. 71906-1915, 2001.
[23] Ibid.
[24] Clarke B, Chetty R Postmodern Cancers: the
role of HIV in uterine cervical cancer. Mol Path 2002;55:19-24
doi:10.1136/mp.55.1.19
[25] Wang C et al. Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV
infection among South African women. J Infect Dis 203(4):479-86, 2011.
[26] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007.
[27] Hogewoning CJ et al. Condom
use promotes regression of cervical intraepithelial neoplasia and clearance of
human papillomavirus: a randomized clinical trial. Int J Cancer 107:811-816,
2003.
[28] Anastos K Risk factors for cervical precancer and
cancer in HIV-infected, HPV-positive Rwandan women. PLoS One. 2010 Oct 20;5(10):e13525.
[29] WHO Comprehensive cervical cancer control: A guide to essential practice.
2006. Geneva.
[30] Ibid.
[31] Ibid.
[32] Ibid.
[33] Sankaranarayanan R, Budukh AM, Rajkuma R Effective Screening programmes for
cervical cancer in low- and middle-income countries. Bulletin of the World
Health Organization, 2001, 79 (10).
[34] HakamaMet al., eds. Screening for cancer of
the uterine cervix. Lyon,
International Agency for Research on Cancer, 1986 (IARC Scientific Publications
No. 76).
[35] Prabhakar AK
Cervical cancer in India
strategy for control. Indian Journal of Cancer, 1992, 104: 29–32.
[36] Murthy NS
et al. Estimation of reduction in
life-time risk of cervical cancer through one life-time screening.
Neoplasma, 1993, 40: 255–25.
[37] WHO
Comprehensive cervical cancer control: A guide to essential practice. 2006. Geneva.
[38] Ibid.
[39] Sankaranarayana R Effective screening programmes
for low- and middle-income developing countries. Bull World Health Organ vol.79 no.10 Geneva 2001.
[40] Sasieni P Has cytology become obsolete as a primary
screening tool for cervical cancer? J Med Screen 2010;17:2-3.
[41] WHO Comprehensive cervical cancer control: A guide to essential practice.
2006. Geneva.
[42] Sankaranarayana R et al. HPV screening for cervical
cancer in rural India.
N Engl J Med 2009;360:1385-94
[43] Cuzick, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for
cervical cancer screening in developed and developing countries. Vaccine 26 supp 10, K29-K41, 2008.
[44] Velázquez-Hernández
N, Sánchez-Anguiano
LF et al. Comparison
of the diagnostic utility from visual inspection with acetic acid and cervical
cytology. Ginecol Obstet Mex. 78(5):261-7, 2010.
[45] Kuhn L et al. Efficacy of human papillomavirus-based
screen-and-treat for cervical cancer prevention among HIV-positive women. AIDS
24: 2553-2561, 2010.
[46] Denny L et al. Screen-and-treat approaches for cervical cancer
prevention in low-resource settings. A randomized controlled trial. JAMA 294
(17): 2173-2181, 2005.
[47] Bardaro L Cervical cancer screening issues for HIV-positive women. BETA. 1996 Jun:35-8.
[48] Parham GP et al. Building a cervical cancer prevention program
into the HIV care and treatment infrastructure in Zambia. In: From the ground up:
Building comprehensive HIV/AIDS care programs in resource-limited settings.
Establishing a framework for success. Elizabeth Glaser Pediatric AIDS
Foundation. http://ftguonline.org/ftgu-232/index.php/ftgu/article/download/1988/3973.
[49] Duerr A, Kieke B, Warren D, Shah K, Burk R, Peipert JF, et al. Human papillomavirus-associated cervical cytologic abnormalities among
women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 184(4):584-90, 2001.
[50] Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD et al.
Women' s Interagency HIV Study Group. Prevalence and predictors
of squamous cell abnormalities in Papanicolaou smears from women infected with
HIV-1. J Acquir Immune Defic Syndr 21(1):33-41, 1991.
[51] La Ruche G, Ramon R, Mensah-Ado I, Bergeron C, Diomande M, Sylla-Koko F, et al.
Dyscer-CI Group. Squamous
intraepithelial lesions of the cervix, invasive cervical carcinoma, and
immunosuppression induced by human immunodeficiency virus in Africa.
Cancer 82(12):2401-8, 1998.
[52] Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected
women. JAMA 283(8):1031-7, 2000.
[53] Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H et al. Evolution of cervical abnormalities among women with HIV-1: evidence
from surveillance cytology in the women's interagency HIV study. J
Acquir Immune Defic Syndr 27(5):432-42, 2001.
[54] Omar T et al. Progression and regression of premaligant cervical lesions in
HIV-infected women from Soweto:
a prospective cohort. AIDS, online edition: DOI: 10.
1097/QAD.0b013e328340fd99, 2010.
[55] Chalermchockcharoenkit A et al. Prevalence and cumulative
incidence of abnormal cervical cytology among HIV-infected Thai women: a
5.5-year retrospective cohort study. BMC Infectious Diseases 2011,
11:8
[56] Agaba PA, Thacher TD, Ekwempu CC, Idoko JA Cervical dysplasia in Nigerian women infected with
HIV. Int J Gynaecol Obstet 107(2):99-102, 2009.
[57] Parham G et al. Effectiveness of a programme to prevent cervical
cancer among HIV-infected women in Zambia. Seventeenth Conference on
Retroviruses and Opportunistic Infections, San Francisco, abstract 29, 2010.
[58] Ibid.
[59] Batra P et al. Utilisation
and outcomes of cervical cancer prevention services among HIV-infected women in
Cape Town. S Afr Med J. 100(1):39-44, 2010.
[60] Strengthening cervical cancer prevention
and control. Report of the GAVI–UNFPA–WHO meeting, 1 December 2009, Geneva.
[61] Dal Maso
L et al. Self-reported history of
Pap-smear in HIV-positive women in Northern Italy:
a cross-sectional study. BMC Cancer. 2010;
10: 310.
[62] Arrossi
S, Paolino M, Sankaranarayanan R Challenges faced by
cervical cancer prevention programmes in developing countries: a situational
analysis of programme organization in Argentina. Rev Panam
Salud Publica. 2010;28(4):249–57.
[63] Brown
DR et
al. The impact of quadrivalent human papillomavirus (HPV;
types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and
disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged
16–26 years. J Infect Dis 199: 926-935, 2009.
[64] WHO Position paper: Human papillomavirus vaccines. Geneva 2009.
[65] Ibid.
[66] See www.gardasil.com
[67] WHO Position paper: Human papillomavirus vaccines. Geneva 2009.
[68] Louie KS et al. Epidemiology and prevention of human papillomavirus and cervical cancer
in sub-Saharan Africa: a comprehensive review. Tropical Medicine and International Health
volume 14 no 10 pp 1287-1302, 2009.
[69]Ibid.
[70] De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S & Temmerman M
Human papillomavirus types in women with invasive
cervical carcinoma by HIV status in Kenya. International Journal of
Cancer 122, 244–246. 2008/
[71] Louie KS et al. 2009, op cit.
[72] Hildesheim A et al. Effect of human papillomavirus 16/18 L1 viruslike
particle vaccine among young women with preexisting infection: a randomised
controlled trial. JAMA 298: 743 – 753, 2007. See also: Markowitz LE HPV vaccines –
prophylactic not therapeutic. JAMA 298: 805-806, 2007.
[73] The Future II Study Group Prophylactic efficacy of a quadrivalent human
papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
J Infect Dis 196: 1438 – 1446, 2007.
[74] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007
[75] WHO Position paper: Human papillomavirus vaccines. Geneva 2009.
[76] Kim JJ et al. Modelling cervical cancer prevention in developed countries.
Vaccine.2008, 26(Suppl 10):K76–K8.
[77] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007.
[78] WHO Position paper: Human papillomavirus vaccines. Geneva 2009.
[79] WHO Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points
for policy-makers and health professionals. Geneva 2007.
[80] Wawer MJ et al. Effects of circumcision of HIV-negative men on transmission
of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. The
Lancet, early online publication, January 7, 2011. and: Giuliano AR et al. Male circumcision and HPV transmission to
female partners. The Lancet, early online publication, January 7, 2011. Full
text available here.
[81]Kuhn 2010, op cit.
[82] National Cancer Institute http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page2
[83] Sittas F et al. Cancer in indigenous Africans - causes and control.
Lancet Oncol 9: 786-95, 2008.
[84] Ndlovu N Radical radiotherapy for carcinoma
of the cervix--the Zimbabwean experience. Cent Afr J Med 45(5):124-7, 1999.
[85] McArdle O, Kigula-Mugambe JB Contraindications to cisplatin based
chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa.
Radiother Oncol. 2007 Apr;83(1):94-6.
[86] Long HJ et al. Randomized phase III trial of
cisplatin with or without topotecan in carcinoma of the uterine cervix: a
Gynecologic Oncology Group Study. J Clin Oncol. Jul 20 2005;23(21):4626-33,
2005.
[87] Monk BJ et al. Phase III trial of four cisplatin-containing doublet
combinations in stage IVB, recurrent, or persistent cervical carcinoma: a
Gynecologic Oncology Group study. J Clin Oncol. Oct 1 2009;27(28):4649-55,
2009.
[88] Mannak M Cervical cancer hits poor women hardest.
www.iafrica.com. 15 November 2009.
[89] Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD Multiple
recurrences of cervical intraepithelial neoplasia in women with the human
immunodeficiency virus. Obstet Gynecol 1996; 87: 338–344.
[90] Omar T et al. Progression and regression of premaligant cervical lesions in
HIV-infected women from Soweto:
a prospective cohort. AIDS 25 (1): 87-94, 2011.
[91] Harris TG et al. Association of cutaneous anergy with human
papillomavirus and cervical neoplasia on HIV-seropositive and seronegative
women. AIDS 21: 1933-1941, 2007.
[92] Ibid.
[93] Shrestha S et al. The impact of highly active
antiretroviral therapy on prevalence and incidence of cervical human papilloma
virus infections in HIV-positive adolescents. BMC Infectious Diseases, 10:295
doi:10.1186/1471-2334-10-295, 2010.
[94] Reimers LL, Sotardi S, Daniel D et al. Outcomes after an excisional procedure for cervical intraepithelial
neoplasia in HIV-infected women. Gynecol. Oncol. 119, 92-97 (2010).
[95] Ibid.
[96] Taylor S et al. Reduced acquisition
and reactivation of human papillomavirus infections among older women treated
with cryotherapy: results from a randomized trial in South Africa. BMC Med. 2010 Jun 29;8:40.
[97] Harding R, Higginson IJ Palliative care in sub-Saharan Africa: an
appraisal. The Diana, Princess of Wales
Memorial Fund, Kings College, London,
2004.
[98] Fernandes
WC, Kimura M Health related quality of life
of women with cervical cancer. Rev Latino-Am Enfermagem 18(3):360-7, 2010.
[99] Herzog TJ, Wright JD The impact of cervical cancer on quality of
life. The components and means for management. Gynecologic Oncology 107(3):572-577,
2007.
[100] Bond C, Lavy V, Wooldridge R Palliative Care Toolkit. Improving care from the roots up in resource-limited
settings. Help for the Hospices. London,
UK, 2008.
[101] Larsen JV Palliation of
recurrent carcinoma of the cervix in a district hospital. South African Medical
Journal 91(3):182, 2001.
[102] Fernandes
W op cit.
[103] Taylor S et
al. Acquisition
and reactivation of human papillomavirus infections among older women treated
with cryotherapy: results from a randomized trial in South Africa. BMC Medicine 8:40, 2010.
[104] Bond op cit.
[105] Larsen op cit.
[106] Moscicki
AB, Weinberg A, Song LY et al.
Safety and immunogenicity of Gardasil in HIV infected Children. Programmes and
Abstracts of the 25th International Papillomavirus Conference and Clinical
Workshop; May 8-14 2009; Malmo,
Sweden
(Abstract O-16.02)